These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6105800)

  • 21. Dopaminergic supersensitivity: influence of dopamine agonists and drugs used for the treatment of tardive dyskinesia.
    Christensen AV; Nielsen IM
    Adv Biochem Psychopharmacol; 1980; 24():341-9. PubMed ID: 6105784
    [No Abstract]   [Full Text] [Related]  

  • 22. Pathophysiologic basis of tardive dyskinesia.
    Baldessarini RJ; Tarsy D
    Adv Biochem Psychopharmacol; 1980; 24():451-5. PubMed ID: 6105793
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of tardive dyskinesia.
    Hollister LE
    Curr Psychiatr Ther; 1980; 19():89-97. PubMed ID: 6109597
    [No Abstract]   [Full Text] [Related]  

  • 24. Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
    Friedhoff AJ; Rosengarten H; Bonnet K
    Psychopharmacol Bull; 1978 Oct; 14(4):77-9. PubMed ID: 704769
    [No Abstract]   [Full Text] [Related]  

  • 25. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
    Baron MS; Dalton WB
    Mov Disord; 2003 Oct; 18(10):1208-9. PubMed ID: 14534933
    [No Abstract]   [Full Text] [Related]  

  • 26. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Quetiapine treatment of risperidone-related tardive dyskinesia. A case report].
    Alcantara Lapaz AG; García Fernández L; Martínez MJ
    Actas Esp Psiquiatr; 2003; 31(5):306. PubMed ID: 14557956
    [No Abstract]   [Full Text] [Related]  

  • 28. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine.
    Bouckaert F; Herman G; Peuskens J
    Int J Geriatr Psychiatry; 2005 Mar; 20(3):287-8. PubMed ID: 15770692
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of conventional antipsychotic-induced tardive dyskinesia.
    Margolese HC; Ferreri F
    J Psychiatry Neurosci; 2007 Jan; 32(1):72. PubMed ID: 17245473
    [No Abstract]   [Full Text] [Related]  

  • 31. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tardive dyskinesia: prevention and treatment.
    Tanner CM; Klawans HL
    Clin Neuropharmacol; 1986; 9 Suppl 2():S76-84. PubMed ID: 2885089
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention and treatment of tardive dyskinesia.
    Med Lett Drugs Ther; 1979 Apr; 21(8):34-5. PubMed ID: 34784
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa and receptor sensitivity modification in tardive dyskinesia.
    Casey DE; Gerlach J; Bjørndal N
    Psychopharmacology (Berl); 1982; 78(1):89-92. PubMed ID: 6128757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Life-threatening tardive dyskinesia.
    Chiu HF; Chung DW; Wing YK; Wong CK
    Br J Clin Pract; 1996; 50(3):175-6. PubMed ID: 8733342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dystonia associated with low-dose of amisulpride: a case report.
    Sevincok L; Balci V; Akyildiz U
    J Clin Psychopharmacol; 2008 Oct; 28(5):573-4. PubMed ID: 18794659
    [No Abstract]   [Full Text] [Related]  

  • 37. [Tardive dyskinesia: pergolid, a possible therapeutic option].
    Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
    Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
    Bona JR
    J Clin Psychopharmacol; 2006 Apr; 26(2):215-6. PubMed ID: 16633158
    [No Abstract]   [Full Text] [Related]  

  • 39. [Tardive dyskinesia: etiology, clinical features and therapy].
    Furer V; Lichtenberg P; Heresco-Levy U
    Harefuah; 2001 Mar; 140(3):248-52. PubMed ID: 11303354
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.